ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0001180.1|Isopropylstilbene_1 # 1 # 2010 # 1 # ID=1_1;partial=10;start_type=Edge;rbs_motif=None;rbs_spacer=None;gc_cont=0.474	BGC0001180.1|Isopropylstilbene_1 	1	2010	+	Loose	500	27.335	APH(3')-IIa	25.78	3002644	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic inactivation	APH(3')	AGGAAAAAGAGAGTGATAGACGTACAGATCAATGAAGTACCTCTTAAGGAACACAGCCCTTCAATTAATGATTGTTTGGATGAGCAAAAGTTACTTTATGACATGCTGCTGTCACGGGAATTTGATAATCGTAGTGCGATAGTCACACGACAAGGCCGAGCTTGGTTTCATGTGTCGGCTGCTGGACATGAAGGGTTGGCTGTGTTGCCTCAGCTTATGGAAAAAAATGATGTACTGGTTCCTTACTATCGTGATCGGGCGTTAGTATTAGCGCGTGGTATGTCTATTGTTGAAATGACAAGGGAACTTATGGGTAAGGCCACTTCTCACTCGGCCGGCCGAACCATGTCGAATCATTTCTGCTCCAAAGAGCATAATATCTTCTCGGTAGTCAGCTTGACCGGAACCCAATGTATTCCCGCGGCTGGCGCTGCTTGGGCAAGCGTGTTGGACAATAAAAATGGGCTTGTTGTGTGTGGTGTCGGCGATGCGGCAACTCGGCAGGGAGAATTTTATGAAGCGGTCAGCTTTGCGGTTGAAAAGCGTTTGCCAGTCGTCTTTGTGGTTTCCGATAATAAATTGGGTATTAGTACCTCAACGGAGAAGATGGCTCCGTATCGATTGGGAATATTTAACGAGTGTTTGATCCGTCGTGTTGATGCCCGTAAGCCGGAAACTTTGTTTACTGTTGCACAGGAGGTATTCAATAAGGCGCGATTTGAGCGGACTCCCTGCATATTGGTTTGTCGTATGGATCGGTTAGATTCTCACTCCAATTCAGATTCTCACAAACTGTACCGTACCCCGGATGAGCTGGAGGTACTACAGGACCCTATTGAAAATTACGTCGCTTATTTAAAGGAAAAAGGAGCGATTACCGAGCAAGCTCTGGCTGAACAAAAAGAGCGCATTAAAGCGGATGTCGCGGAAATATTTGAGCGTGTTTACCACGAAGAAGAGCCTGATCCTGCAAGTGTCAGTACCTATTTATGCAATCGTGAAGGGACGCCTACCGTACATGTTGAGATGGAAGCCGAAGAGACACAGGTCAAAGCGGTAAATCAAGTTTTGGACGAGGCATTGAGTCAGCATCCGAATGTGCTGATATTTGGTGAGGATATTGAAGATCCTAAAGGTGGTGTTTTTGGTTTCACCCGTGGCTTATCCACTCGCTATCCTGATCGCGTTATTAATGCTCCCCTTTCCGAAGCCACGATTATTGGCTCGTCTGTTGGGTTATCTGCCAGTGGTTGGCGTCCGATTGTTGAACTGCAATTTATTGACTTTGTTGGGCTAGGTCTCAATCAGTTACAGTCACAACTTGGCACTTTAAGTTGGAGAACGGTGGGAAAATGGCGCTGTCCGGTGGTGATATATGCTCCTTATGGCGCTTATCTCCCTGGCGGTGGTATATGGCACAGCCAAAGCTCGGACGGTATCCTGGCGCATATTCCCGGTATTAACGTTCTGGTTCCAACGACACCGGCTGATACCGTCGCGTTGTTCCGTACCGCGTTAAGTCTGGACATGCCGAGTCTGATTCTGATCCCTAAACACCTTATGAGAGAGCGCCATGAACGCCGGCTGGTGAGTCCAGTGTCGCTTGGGCAGGCAAATATCGTCAGGGCAGGAAAGGACATTACACTGGTTGCTTGGGGAAATACGACTCAGCTTGCGACGATGGCGGCTCTTCAGGCGGAAAAAGACAATATTGACATTGAAGTGATTGAATTACGTAGTCTGGTACCTTGGGATAAACAACGGATTGCGGAATCTTTACGCAAAACCGGGCGGCTTATCGTTGTGCAGGAGGATACCCGGACGGCCAGTGTTGGTGCATCCATTATTGCTGATATTTTGGATGAGAATGACAATTTCTTCTCTTTATTGGCACCTCCGCGTTTGGTGACGCGTGAAGATATTCATATTCCTTTTAATCCTTGTTTAGAGAAAGCTGTTTTACCCGGCACGGATGACATTTTAGCCTCCGTCTATGCGGTAATGAGCTAA	RKKRVIDVQINEVPLKEHSPSINDCLDEQKLLYDMLLSREFDNRSAIVTRQGRAWFHVSAAGHEGLAVLPQLMEKNDVLVPYYRDRALVLARGMSIVEMTRELMGKATSHSAGRTMSNHFCSKEHNIFSVVSLTGTQCIPAAGAAWASVLDNKNGLVVCGVGDAATRQGEFYEAVSFAVEKRLPVVFVVSDNKLGISTSTEKMAPYRLGIFNECLIRRVDARKPETLFTVAQEVFNKARFERTPCILVCRMDRLDSHSNSDSHKLYRTPDELEVLQDPIENYVAYLKEKGAITEQALAEQKERIKADVAEIFERVYHEEEPDPASVSTYLCNREGTPTVHVEMEAEETQVKAVNQVLDEALSQHPNVLIFGEDIEDPKGGVFGFTRGLSTRYPDRVINAPLSEATIIGSSVGLSASGWRPIVELQFIDFVGLGLNQLQSQLGTLSWRTVGKWRCPVVIYAPYGAYLPGGGIWHSQSSDGILAHIPGINVLVPTTPADTVALFRTALSLDMPSLILIPKHLMRERHERRLVSPVSLGQANIVRAGKDITLVAWGNTTQLATMAALQAEKDNIDIEVIELRSLVPWDKQRIAESLRKTGRLIVVQEDTRTASVGASIIADILDENDNFFSLLAPPRLVTREDIHIPFNPCLEKAVLPGTDDILASVYAVMS	MIEQDGLHAGSPAAWVERLFGYDWAQQTIGCSDAAVFRLSAQGRPVLFVKTDLSGALNELQDEAARLSWLATTGVPCAAVLDVVTEAGRDWLLLGEVPGQDLLSSHLAPAEKVSIMADAMRRLHTLDPATCPFDHQAKHRIERARTRMEAGLVDQDDLDEEHQGLAPAELFARLKARMPDGEDLVVTHGDACLPNIMVENGRFSGFIDCGRLGVADRYQDIALATRDIAEELGGEWADRFLVLYGIAAPDSQRIAFYRLLDEFF	253.41	gnl|BL_ORD_ID|1912|hsp_num:0	2114			15	360	neomycin; ribostamycin; butirosin; kanamycin A; gentamicin B; paromomycin; gentamicin
BGC0001180.1|Isopropylstilbene_2 # 2020 # 3585 # 1 # ID=1_2;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.465	BGC0001180.1|Isopropylstilbene_2 	2020	3585	+	Loose	700	28.1054	ADC-135	32.81	3006310	protein homolog model	n/a	n/a	cephalosporin	antibiotic inactivation	ADC beta-lactamases pending classification for carbapenemase activity	ATGGCACAGTTGCTTATTCCCCCGATGGGAGAAGGAACCACTGAAGTCGTCATCATCCAATTACTTAAGCAGGTAGGGGATCATGTCAAACGTGATGAACCTGTTTATGAAATGGAGACGGATAAGGCTGCCTTTACCATTGAATCTGATGTTGAGGGGATCTTGGAAAAATGGTTGGCGGCGGAAAATGATATTATCCCTGTTGGATCTCCTATTGCCGTTATCAGAGCTGTTGGCGAGATGGCAGAGCCTTCCCCTGTCAGTGAAGCGTTAACGCCTCCGCCGGAGAAAATGGAGAGAGTGGCGGAGGATGTCGAAAAAATAGAGAAAGTGGAGGCGGCTCCTGAAGTCTCCGCTCCTCCTGCGCGTATTCCGCCAAAAACCCGTCAGTACGCACAAGAGCACCAAATTGAGCCACTCATTCTTAGTCAACTGGCGGAAAAACATGGCACATTATTGCCTGGTCATATAGATGATTACCTCCAGCAGCACCGCGAAACTAAGATATCAGAAGAAACCAGGCCATCAGAAAAGAGCAATACAGAAAATGACAATGTGGGTTTTCTGTCCAGAGATCAGCAGCGTCTTAATCGTGCAATACGGTTAAATAGTGCTGCGGTACAACCTTGTTGGGCAGCTAAACCACTACCGATTGAGCTTGTTGATAACGCCATTCATCATTTAACGGAAACCTCCGGGCAGCAGGAGTGGATAACGCCATTTCAGGTCATCACTTATGCGATTTCTCAGGCGTTGAAAAAATTCCCGATGTTGCGTTCGAGACCGCTTGATCAGGAGCGTTATCACACTTATACGGATATCAACTTGGGTATTGCTTTTCTGGATGAGAAAGGCGATTTGAGTTCATTAAAAGTACCGAACACGCAGACCATGAGCTTTTTTGAGTTCAGGCAACACTTGAATGGTGTACTTGATCCCGATGCGGAAAAACTGCCTGTTGATATTGATGTTCCTATGATGATCTCCTATACCGGCAACGATGGTGCTACCTTTGCCGTACCTGTTATTGTGCCGCCATCTCAGTCAACATTGTTCATTGGTGCGCCTCACAACAAAGAGATGAGCCTCGTTCTGGCCTTTAATCACTATCTGCTCAATGGGGTAGAGGCATCTGAGTTTATTTCCGAGATTATTGTTCAGGTTCGTGCTCTGTCTGGGCCACGATCTGCCGCACATCAGATAGAAGGTAAAGTAGGTAAATCGGTTTCCGGGCAATTACGCACGTTGCTGGCGGATTTCCTGCATTGGGACGAAGATTTTACTGAATCAATGATGCCGCGCACTTGGGCTGATTTGGGCATTGATTCGCTCAAGGCAGTAAAGCTTGCAGAGTTAATGTCAGTGCATTTTCGTCGGAAATTATCGCCGACGCTGTTCTGGCGTTATAGTTCACCGCATCGATTGATTGAATATCTTGACACTGCCAAAACTGAACTGACTGAGAACAAACATTCCTTAGATGACTTTATTAATGCGATGCGTGGTCTTGATGGCGAAGCAGCATTAAGGTTACAGCGCCTCATAGAAGGAGGAAAGCATGGATAA	MAQLLIPPMGEGTTEVVIIQLLKQVGDHVKRDEPVYEMETDKAAFTIESDVEGILEKWLAAENDIIPVGSPIAVIRAVGEMAEPSPVSEALTPPPEKMERVAEDVEKIEKVEAAPEVSAPPARIPPKTRQYAQEHQIEPLILSQLAEKHGTLLPGHIDDYLQQHRETKISEETRPSEKSNTENDNVGFLSRDQQRLNRAIRLNSAAVQPCWAAKPLPIELVDNAIHHLTETSGQQEWITPFQVITYAISQALKKFPMLRSRPLDQERYHTYTDINLGIAFLDEKGDLSSLKVPNTQTMSFFEFRQHLNGVLDPDAEKLPVDIDVPMMISYTGNDGATFAVPVIVPPSQSTLFIGAPHNKEMSLVLAFNHYLLNGVEASEFISEIIVQVRALSGPRSAAHQIEGKVGKSVSGQLRTLLADFLHWDEDFTESMMPRTWADLGIDSLKAVKLAELMSVHFRRKLSPTLFWRYSSPHRLIEYLDTAKTELTENKHSLDDFINAMRGLDGEAALRLQRLIEGGKHG	MRFNKISCLLLSPLFIFNTSIYAENTPKEQEIKKLVDQNFKPLLEKYDVPGMAVGIIQNNKKYEMYYGLQSVQDKKAVNSSTIFELGSVSKLFTATAGGYAKTKGIISFKDTPGKYWKELKNTPIDQVNLLQLATYTSGNLGLQFPDEVQTNQQVLTFFKDWKPKNSIGEYRQYSNPSIGLFGKVVALSMNKPFDQVLEKTIFPDLGLKHSYVNVPKTQMQNYAFGYNQENQPIRVNPGPLDAPAYGVKSTLPDMLSFVNANLNPQKYPADIQRAINETHQGFYQVGTMYQALGWEEFSYPAPLQTLLDSNSEQIVMKSNKVTAISKEPSVKMFHKTGSTNGFGTYVVFIPKQNIGLVMLTNKRIPNEERIKAAYAVLNAIKK	136.03	gnl|BL_ORD_ID|3168|hsp_num:0	4206			357	528	
BGC0001180.1|Isopropylstilbene_3 # 3578 # 5428 # 1 # ID=1_3;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.461	BGC0001180.1|Isopropylstilbene_3 	3578	5428	+	Loose	750	75.0998	Mycobacterium tuberculosis kasA mutant conferring resistance to isoniazid	27.52	3003463	protein variant model	G269S	n/a	isoniazid-like antibiotic	antibiotic target alteration	antibiotic resistant kasA	ATGGATAATCTGCACCACATATATCATTCGCTTAGTCCGGATGAACAACGGATAGCTAAATCTGCCTTGTTGGAACATTTAAGTTCCATTACTCCCTCAGTAAGTAGTGCGGGTGATACCAAACAGATGCCTATTGCTATTGTGGGCATGGCTTTCCGACTGCCTGGAGCGGAAGATTCCCCAGAGCAAATGTGGGAGATCTTAAGATCTGGACACAGTGTAATAAAAGAGATTCCCGAGCAGCGGTTTGCATCCGGGAAACCTTACGTCATTCCATTGCCGAAAAAAGCCTTAAAAGCCGGGTTGCTCGATAGTATTGATGGTTTTGATGCGCCATTCTTTGGTATTTCTCCGCGAGTTGCGGCCATGATGGATCCGCAACAGAGAATGCTATTAGAGCTGACTTGGCAAGCGATCGAAGATAGTGGTGCGAATCCGCTTGGCTATTCAGGATCAAAGACGGGTGTTTTTATTGGCTCGTGCAGTAATGATTATCGTGAACTGGTTGCGGCCGATATGGCGATGGCAAATGCTTATGCGCCGACAGGGACACTGAATTGCCTCTTGGCTAACAGATTGTCATTTTATTACAACTTTATTGGCCCAAGTTTGCAAATTGATACCGCGTGTTCAAGTGGATTGACGGCACTGACTCAAGCGGTGAATTCATTGCGTTCTGGGGAATGCCAACAGGCGATAGTTGGCAGCGTTAACTTATTGAGCAACACATTCAACATGGCTGCTTATTACCGGGCGGGGATGTTATCTAAAGATGGCTGTTGTAGGGTTTTTGACGCGGATGCTAATGGTTTTGTCCGTGGTGAAGGGGCTATCTGTCTATTCTTGAAAACGCAAAAACAGGCATTAGAGGATCGGGATCCGATTTATGGATACGTTCGGGCATCGGCGGTTAATCATGGTGGACGTGCTAATTCACTGACTTCACCTAACCCTGAGCAGCAAATTGCGTTGGTTAAAGATTGCTTGCTACAGGCTGGAATTTCTGCGGAACAAATCAGTTACCTTGAAGCACATGGAACGGGAACCTCGTTGGGTGATCCTATAGAATTTAATGCGCTTAATGAGGTCTTTAATCGCGATGAATCAGGAGGAACGCTACAACCTTGCTATATTGGTTCAGTAAAAGCCAACATTGGGCATTTAGAAGGCGCTGCGGGGTTAGCTGGCATCGTTAAAGTTTTATTAATGTTGCAGCATAAATCTATTGTACCTAGCGCTGCGTTTCAGCGTTTGAATCCTGAAATTGATAGTGTGGATTCACGTTTACAACTGGCTACAGAGGAAAATTCTTGGCGAGTGGGGGCAGGGCAAAAGCGTTTCGCTGGACTCAGCTCTTTTGGATTGGGGGGCAGCAATTCCCATGTCATTTTAGAGGAGGCACCAACCCAAGCGCAGCAACAGATTAAAGCCAACCTGGAGGGGTATTATTATCCCATCTCGGCTAATAGCCAGGCATCGTTACAAAAAATAGTGGCTATGCTAGGGGATTTTATCGAGAATGATGAAAGCGTTGAACTACCAGCGGTTAGCTGGACATTACAGTTTGGCAGGGCAGCGTTATCCTATCGGGCACTGTTCGTTGCAACATCACGACAGGATCTTTTGAAGCAGTTACGGGATTTTGCTTCGTCTACGGCAACGAAAGAAGATCAATGGCTTCATATGGCGGAAGATGACTCTCGATTTTTATGGTTACGAGGTCAAGATATAGATTGGCGTACTTGCTGGCCTTCCGGGCAGAAACCGTTGCGTATTCGATTACCCAAATATGCTTTTGAACATCGGCGTTACTGGTTACCTCACAATGAATCCGTGGTTGCAAAACAGTAA	MDNLHHIYHSLSPDEQRIAKSALLEHLSSITPSVSSAGDTKQMPIAIVGMAFRLPGAEDSPEQMWEILRSGHSVIKEIPEQRFASGKPYVIPLPKKALKAGLLDSIDGFDAPFFGISPRVAAMMDPQQRMLLELTWQAIEDSGANPLGYSGSKTGVFIGSCSNDYRELVAADMAMANAYAPTGTLNCLLANRLSFYYNFIGPSLQIDTACSSGLTALTQAVNSLRSGECQQAIVGSVNLLSNTFNMAAYYRAGMLSKDGCCRVFDADANGFVRGEGAICLFLKTQKQALEDRDPIYGYVRASAVNHGGRANSLTSPNPEQQIALVKDCLLQAGISAEQISYLEAHGTGTSLGDPIEFNALNEVFNRDESGGTLQPCYIGSVKANIGHLEGAAGLAGIVKVLLMLQHKSIVPSAAFQRLNPEIDSVDSRLQLATEENSWRVGAGQKRFAGLSSFGLGGSNSHVILEEAPTQAQQQIKANLEGYYYPISANSQASLQKIVAMLGDFIENDESVELPAVSWTLQFGRAALSYRALFVATSRQDLLKQLRDFASSTATKEDQWLHMAEDDSRFLWLRGQDIDWRTCWPSGQKPLRIRLPKYAFEHRRYWLPHNESVVAKQ	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY	148.08	gnl|BL_ORD_ID|1968|hsp_num:0	1943			504	1224	isoniazid
